Martin Bentz
Overview
Explore the profile of Martin Bentz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1683
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rucker F, Corbacioglu A, Krzykalla J, Cocciardi S, Lengerke C, Germing U, et al.
Hemasphere
. 2024 Jul;
8(7):e123.
PMID: 39011127
No abstract available.
2.
Lugnier C, Sommerlatte S, Attenberger U, Beer A, Bentz M, Benz S, et al.
Oncol Res Treat
. 2024 Mar;
47(6):296-305.
PMID: 38484712
In the context of the COVID-19 pandemic, there has been a scarcity of resources with various effects on the care of cancer patients. This paper provides an English summary of...
3.
Thurner L, Ziepert M, Berdel C, Schmidt C, Borchmann P, Kaddu-Mulindwa D, et al.
Hemasphere
. 2023 Jul;
7(7):e904.
PMID: 37427146
UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18-60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic Index...
4.
Korper S, Gruner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R, et al.
J Clin Invest
. 2022 Nov;
132(24).
PMID: 36326824
BACKGROUNDResults of many randomized trials on COVID-19 convalescent plasma (CCP) have been reported, but information on long-term outcome after CCP treatment is limited. The objectives of this extended observation of...
5.
Korper S, Schrezenmeier E, Rincon-Arevalo H, Gruner B, Zickler D, Weiss M, et al.
Front Immunol
. 2022 Oct;
13:1008438.
PMID: 36275695
Objectives: To determine the profile of cytokines in patients with severe COVID-19 who were enrolled in a trial of COVID-19 convalescent plasma (CCP). Methods: Patients were randomized to receive standard...
6.
Sasse S, Brockelmann P, Momotow J, Plutschow A, Huttmann A, Basara N, et al.
Leuk Lymphoma
. 2022 Jul;
63(8):1871-1878.
PMID: 35848865
In patients with relapse of classical Hodgkin lymphoma (cHL) after autologous stem cell transplant, brentuximab vedotin and anti-PD1 treatment, the outcome is poor. To assess the efficacy of the bispecific...
7.
Korper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman V, et al.
J Clin Invest
. 2021 Aug;
131(20).
PMID: 34464358
BACKGROUNDCOVID-19 convalescent plasma (CCP) has been considered a treatment option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring...
8.
Kiani A, Roesch R, Wendtner C, Kullmann F, Kubin T, Sudhoff T, et al.
Cancer Med
. 2021 Jun;
10(13):4424-4436.
PMID: 34121360
Background: Infection with SARS-CoV-2 leads to COVID-19, the course of which is highly variable and depends on numerous patient-specific risk factors. Patients with tumor diseases are considered to be more...
9.
Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, et al.
Lancet Haematol
. 2021 May;
8(6):e398-e409.
PMID: 34048679
Background: The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the treatment...
10.
Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al.
Lancet Haematol
. 2021 Mar;
8(4):e267-e277.
PMID: 33667420
Background: R-MegaCHOEP was the first phase 3 study comparing high-dose chemotherapy plus rituximab followed by autologous haematopoietic stem-cell transplantation (HSCT) with conventional chemotherapy plus rituximab in first-line therapy for patients...